India’s healthcare sector is entering a new phase of expansion, but the next big opportunity may not simply come from constructing more hospitals or adding beds. Advances in medicines, artificial intelligence, medical devices, diagnostics and preventive healthcare could fundamentally change how diseases are treated, where patients receive care and how much treatment costs.
These changes could reshape the economics of India’s healthcare industry over the coming decade.
India’s healthcare market is estimated at around ₹7 lakh crore and is projected to approach ₹12 lakh crore by 2030. Private hospitals are expected to remain central to organised healthcare, with the sector attracting nearly $11 billion in private-equity investments since 2021.
However, the post-pandemic growth story could look very different. Instead of relying primarily on physical infrastructure, the next stage may be driven by innovations that prevent illness, enable earlier diagnosis, improve treatment and shift more care away from traditional hospital settings.
GLP-1 Drugs Could Transform Healthcare Demand
The growing popularity of GLP-1 medicines is one example of how pharmaceutical innovation could influence the broader healthcare economy.
Initially developed for diabetes management, GLP-1 drugs have become widely known for their ability to support weight loss and treat obesity. Their long-term significance could extend well beyond these applications if they help reduce the incidence or severity of obesity-related and metabolic diseases.
Dr B S Ajaikumar, Founder and Chairman of Healthcare Global Enterprises (HCG), believes these medicines could significantly alter disease patterns over the next decade.
Speaking to CNBC-TV18 at the Market Forum event, Ajaikumar described GLP-1 drugs as potentially transformative, particularly for conditions such as diabetes and cardiovascular disease, while also pointing to possible implications for diseases including Alzheimer’s.
The economic consequences could be substantial. If medicines can prevent or delay chronic illnesses, patients may require fewer advanced interventions and hospitalisations.
That does not necessarily mean overall healthcare demand will decline. Instead, the nature of demand could change, with greater emphasis on prevention, early detection, nutrition, chronic disease management and healthy ageing.
For hospitals and healthcare companies, this could create entirely new revenue opportunities outside traditional inpatient care.
Healthcare Delivery Is Moving Beyond Hospital Walls
Technology and medical innovation are also changing where treatment takes place.
Traditionally, hospitals have relied heavily on inpatient admissions, bed occupancy, surgeries and procedures. However, minimally invasive techniques, improved diagnostic tools, drug therapies and remote monitoring are making it possible to deliver an increasing amount of care without prolonged hospital stays.
This transition could significantly influence hospital economics.
A procedure that once required several days of admission may now be completed on an outpatient basis. While this could reduce revenue generated from an individual hospital stay, it can also allow healthcare providers to treat a larger number of patients using the same infrastructure.
As a result, hospital performance may increasingly depend not just on revenue generated per occupied bed but on how efficiently providers manage the complete patient journey.
Ajaikumar expects this shift to become increasingly important as healthcare technology reaches tier-II and tier-III cities.
Domestic manufacturing could also help bring costs down. Locally produced MRI machines and other medical equipment, combined with the availability of lower-cost generic medicines, could make healthcare services more accessible in smaller cities.
For hospitals and investors, this development could make average revenue per occupied bed, or ARPOB, a less comprehensive indicator of future growth.
The larger opportunity may lie in providing treatment to more patients while reducing the cost of each episode of care.
Cancer Treatment Shows the Complex Impact of Innovation
Cancer care demonstrates how technological progress can have both positive and challenging economic consequences.
The arrival of newer treatments such as immunotherapy has significantly expanded options for cancer patients. However, innovative therapies can initially increase treatment costs.
Over time, the economics can change as therapies become more widely available, competition grows and domestic production increases. Better diagnostic techniques and targeted treatments can also influence how much treatment patients need and how frequently they require hospital care.
For healthcare providers, therefore, the impact of innovation cannot be assessed simply by comparing the current price of a new medicine or device.
The more important consideration is whether the technology transforms the entire treatment process — from diagnosis and hospitalisation to treatment duration, staffing requirements and patient outcomes.
This is particularly relevant for India, where affordability remains one of the biggest barriers to healthcare access.
Insurance Will Play a Crucial Role in Healthcare Expansion
Medical innovation can alter treatment costs, but healthcare financing will determine how many Indians can actually access those advances.
India’s healthcare financing system remains fragmented, and a significant part of the population does not have comprehensive health insurance.
Vishal Bali, Executive Chairman of Asia Healthcare Holdings, has highlighted the fragmented nature of India’s third-party payer system and the relatively low penetration of health insurance compared with the country’s population.
According to Bali, around 570 million people have some form of health insurance coverage, leaving a large section of the population without adequate financial protection against medical expenses.
This is important because increasing hospital capacity does not automatically guarantee greater healthcare access.
A hospital may add beds, advanced equipment and specialist doctors, but that infrastructure can remain underutilised if patients cannot afford the treatment.
Broader insurance coverage could therefore have a multiplier effect. Greater financial protection could encourage more people to seek treatment, increase healthcare utilisation and support further investment in medical infrastructure.
However, rising healthcare costs present another challenge. If medical expenses continue to grow faster than household incomes, expanding insurance coverage alone may not solve the affordability problem.
Why Insurance Alone Cannot Guarantee Affordable Healthcare
The affordability debate therefore extends beyond insurance.
Ajaikumar has argued that universal healthcare could provide a more direct solution to the financial burden faced by patients. His proposed approach involves broader coverage without restrictive limits on eligible treatments and could include funding through a healthcare cess.
While such a model would require significant policy changes, it highlights an important distinction: expanding the healthcare market does not automatically make healthcare affordable.
Kaivaan Movdawalla, Sector Leader & Partner, Healthcare at EY Parthenon, has similarly argued that insurance is necessary but cannot, by itself, deliver universal healthcare.
The missing element is efficiency — ensuring that healthcare providers achieve better outcomes while controlling the growth in treatment costs.
As advanced and often expensive technologies enter the market, maintaining this balance will become increasingly important.
Innovation that improves outcomes but remains unaffordable for a large section of society will have limited impact. At the same time, excessive cost-cutting that compromises quality could weaken the benefits of greater healthcare access.
Private Equity Is Looking Beyond Traditional Hospitals
The changing healthcare landscape is also influencing where private-equity investors are putting their money.
Earlier waves of institutional investment were heavily focused on hospital expansion, acquisitions and building larger organised healthcare networks. Today, the investment opportunity is spreading across a much wider ecosystem.
Bali said capital is increasingly finding its way into medical technology, hospital support systems and artificial intelligence.
This shift is significant because some of the most important developments in healthcare may not require the construction of another hospital.
An AI platform that reduces administrative workloads, a diagnostic system that identifies disease earlier or a medical device that lowers the cost of treatment could potentially transform the economics of an entire healthcare pathway.
Ajaikumar has also pointed to growing private investment in healthcare startups at early and mid stages.
Consequently, investors are increasingly looking beyond the traditional question of how many hospitals or beds an investment can create.
They are also examining whether technologies can reduce costs, improve utilisation, expand access or fundamentally change how healthcare is delivered.
AI Could Reshape Healthcare Economics
Artificial intelligence is likely to be another major force influencing the sector.
AI applications are emerging across multiple areas, from administrative automation and appointment scheduling to diagnostics, clinical decision-making, patient monitoring and personalised treatment.
For hospitals, these technologies could reduce repetitive manual work, help doctors analyse large volumes of information and potentially identify diseases at earlier stages.
However, AI should not automatically be viewed as a guaranteed cost-saving technology.
Healthcare providers still need to spend on software, data infrastructure, cybersecurity and skilled professionals. The financial benefit will depend on whether these investments generate measurable improvements in productivity, accuracy, utilisation and patient outcomes.
Unlike conventional infrastructure, however, AI has the potential to influence the efficiency of existing healthcare capacity across multiple locations.
A new hospital adds physical capacity in one place. AI could potentially improve the way healthcare capacity is used across the entire system.
The Next Healthcare Boom Could Be Built on Innovation
India’s healthcare sector will continue to benefit from several long-term trends, including rising incomes, an ageing population, expanding insurance coverage and the transition from fragmented healthcare providers to organised networks.
Private hospitals will remain important beneficiaries of this growth.
But the definition of healthcare demand could gradually evolve.
Patients who once required several days of hospitalisation may increasingly receive outpatient treatment. Some chronic illnesses could potentially be delayed or prevented through improved medicines and lifestyle interventions. AI could assist with diagnostic and administrative processes, while domestic manufacturing and greater competition could gradually make advanced treatments and equipment more affordable.
For investors, hospital operators and policymakers, this means healthcare growth may no longer be measured simply by the number of beds added or hospitals opened.
The bigger question will be how many more patients can receive better care, how effectively that care can be delivered, and whether it can be provided at an affordable cost.
Ultimately, India’s next healthcare boom is likely to come from the intersection of technology, prevention, affordability and efficient care delivery. The biggest winners may not simply be the companies that build more hospitals, but those capable of using innovation to improve outcomes, expand access and reduce the overall cost of quality healthcare.